AMYLYX PHARMACEUTICALS, INC. : LEERINK PARTNERS RAISES TARGET PRICE TO $40 FROM $28

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Trade smarter